Last updated: September 2, 2026
Brigatinib, marketed as Alunbrig by Takeda Pharmaceutical, is a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor for ALK-positive metastatic non-small cell lung cancer (NSCLC). Its commercial trajectory has shifted from post-crizotinib salvage treatment to first-line therapy, but the product remains exposed to intense competition from alectinib and lorlatinib. Takeda’s reported Alunbrig revenue has grown since the 2020 first-line approval, although the product is still a relatively small contributor to the company’s total sales.
The main commercial issue is duration of first-line use. Brigatinib has clinically meaningful efficacy, but physicians increasingly compare it with alectinib’s established standard-of-care position and lorlatinib’s strong progression-free survival data. The principal US patent estate appears to provide protection into the early 2030s, with later secondary patents potentially extending protection into the mid-2030s, subject to patent validity, listing status and generic litigation.
How large is the brigatinib market?
Brigatinib competes in the ALK-positive metastatic NSCLC segment, which represents approximately 3% to 7% of NSCLC cases. ALK-positive disease is more common in younger patients, never-smokers and patients with adenocarcinoma histology. The treatment market is concentrated among a small number of targeted therapies rather than broad-based chemotherapy products.
What is the commercial positioning of Alunbrig?
Alunbrig is positioned as:
- A first-line treatment for adults with metastatic ALK-positive NSCLC.
- A treatment for patients whose disease has progressed on crizotinib.
- An oral, once-daily therapy with an initial seven-day lead-in regimen.
- A competitor to Alecensa, Lorbrena and Xalkori.
The FDA granted accelerated approval for crizotinib-pretreated ALK-positive metastatic NSCLC in April 2017. The agency converted brigatinib to regular approval for first-line treatment in May 2020 after results from the phase 3 ALTA-1L trial supported its use in previously untreated patients (FDA, 2017, 2020).
The first-line label materially expanded the addressable market. Before 2020, Alunbrig was primarily a later-line product. After the first-line approval, Takeda gained access to treatment-naive patients, where drug duration and prescribing share have a much larger impact on revenue.
How many patients are eligible for brigatinib?
The commercial pool depends on the incidence of metastatic NSCLC, the ALK-positive rate, testing rates and treatment duration. The global eligible population is likely in the low tens of thousands of new patients annually across major markets. The addressable pool is larger when prevalent patients receiving multiple lines of therapy are included.
ALK testing is a critical market constraint. Molecular testing rates have improved, but uneven testing and access to next-generation sequencing still limit diagnosis in some countries. Broader biomarker testing expands the market for all ALK inhibitors, including brigatinib, while also intensifying competition within the class.
What has Alunbrig’s financial trajectory been?
Takeda reports Alunbrig as part of its oncology portfolio. The product has delivered sustained sales growth following its first-line launch, but it remains considerably smaller than Takeda’s core products, including Entyvio, immunoglobulin products and other gastrointestinal and rare-disease medicines.
Alunbrig revenue trajectory
| Fiscal period |
Commercial development |
Reported or approximate sales direction |
| FY2017 |
US launch in previously treated disease |
Initial commercial ramp |
| FY2018-FY2019 |
Expansion in the US and international markets |
Growth from a small base |
| FY2020 |
FDA first-line approval |
Major market expansion |
| FY2021-FY2022 |
First-line adoption and international reimbursement |
Continued double-digit growth |
| FY2023 |
Broader first-line contribution |
Approximately ¥70 billion in Takeda-reported sales, depending on reporting basis and currency |
| FY2024 onward |
Mature first-line competition |
Growth depends on share retention, pricing and treatment duration |
Takeda’s fiscal year ends March 31. Alunbrig sales rose substantially after the ALTA-1L-based first-line approval, but the drug does not represent a material concentration of Takeda’s consolidated revenue. At approximately ¥70 billion in annual sales against Takeda group revenue above ¥4 trillion, Alunbrig contributes roughly 1% to 2% of company revenue (Takeda Pharmaceutical Company, 2024).
What drives future brigatinib revenue?
The key revenue drivers are:
- First-line prescribing share.
- Persistence before disease progression.
- Uptake in Japan, Europe and other reimbursed markets.
- Physician confidence in intracranial activity.
- Net pricing and payer restrictions.
- The timing of generic entry.
- The rate at which lorlatinib and alectinib displace brigatinib.
Revenue growth is likely to moderate as the ALK inhibitor class matures. Alunbrig can still expand through market growth and treatment duration, but it must defend share in a market where competing products have strong long-term datasets.
How does brigatinib compare with alectinib and lorlatinib?
Alectinib is the leading commercial comparator in first-line ALK-positive NSCLC. Lorlatinib has gained attention because of its deep central nervous system activity and strong results in the CROWN trial. Brigatinib’s competitive position depends on balancing efficacy, tolerability, dosing convenience and physician familiarity.
| Product |
Company |
Main commercial position |
Key competitive attributes |
| Alunbrig, brigatinib |
Takeda |
First-line and post-crizotinib ALK-positive metastatic NSCLC |
Strong systemic and intracranial activity; early pulmonary toxicity monitoring |
| Alecensa, alectinib |
Roche |
Established first-line standard |
Broad adoption, mature safety profile and strong CNS activity |
| Lorbrena, lorlatinib |
Pfizer |
First-line and later-line ALK-positive disease |
High CNS activity and durable disease control; neuropsychiatric and metabolic adverse events |
| Xalkori, crizotinib |
Pfizer |
Earlier-generation ALK inhibitor |
Reduced first-line relevance because of CNS and durability limitations |
| Ensartinib |
Xcovery/partners |
Potential future competitor |
Could add another first-line option if approved |
Is brigatinib clinically differentiated?
The ALTA-1L trial showed brigatinib improved progression-free survival compared with crizotinib in treatment-naive ALK-positive advanced NSCLC. The trial also showed intracranial activity, an important differentiator because the brain is a frequent site of progression in ALK-positive disease (Camidge et al., 2018; FDA, 2020).
Brigatinib has a recognized early pulmonary toxicity risk, particularly during the first week of treatment. The seven-day 90 mg lead-in followed by 180 mg daily was adopted to reduce that risk. Alectinib generally has a more established tolerability profile in routine first-line use, while lorlatinib has its own concerns involving central nervous system effects, lipid abnormalities and weight gain.
The commercial result is a differentiated but contested position. Brigatinib is clinically credible in first-line therapy, but it does not have an uncontested efficacy or safety advantage that eliminates substitution risk.
When does brigatinib lose exclusivity?
US market exclusivity has several components: FDA regulatory exclusivity, listed patents, patent-term adjustment, pediatric exclusivity and any litigation-related stay.
What is the FDA regulatory status of Alunbrig?
The FDA approved Alunbrig in April 2017 for metastatic ALK-positive NSCLC after crizotinib progression. The FDA granted regular approval for first-line treatment in May 2020. The first approval was based on response data and included an accelerated-approval framework; the first-line indication was supported by confirmatory phase 3 data (FDA, 2017, 2020).
The original five-year new chemical entity exclusivity period would have expired in 2022. That date does not determine generic launch by itself because listed patents can continue to block approval or commercial entry.
What patents protect brigatinib?
The principal US composition-of-matter patent family associated with brigatinib includes U.S. Patent No. 8,426,586. Public patent databases identify an expiration date in the vicinity of August 2030, before any applicable patent-term adjustment. Later patent families may cover specific solid forms, formulations, dosing regimens or other product attributes.
A representative patent profile is set out below.
| Patent or protection category |
Subject matter |
Approximate timing |
| U.S. Patent No. 8,426,586 |
Brigatinib-related compound and ALK inhibitor chemistry |
Approximately 2030 expiration before adjustments |
| Later US patents |
Form, formulation, dosing or related pharmaceutical compositions |
Potentially into the mid-2030s |
| FDA NCE exclusivity |
Original active ingredient approval |
Expired in 2022 |
| First-line approval |
Supplemental indication |
Does not restart NCE exclusivity |
The exact commercial blocking date depends on the current Orange Book record, patent-term adjustment, pediatric exclusivity and whether a generic applicant successfully challenges relevant claims. Takeda’s later patents matter because they may create separate obstacles even after expiry of the core composition patent.
What is the Orange Book status of brigatinib?
Alunbrig is a small-molecule prescription product listed in the FDA Orange Book. Its Orange Book profile is relevant to abbreviated new drug application (ANDA) applicants because listed patents can trigger Paragraph IV certification and, if litigation is filed promptly, a statutory 30-month stay.
The commercial importance of each listing depends on whether the patent claims:
- The active ingredient.
- A specific tablet strength.
- The marketed dosage regimen.
- A formulation or solid form.
- A method of treating ALK-positive NSCLC.
An ANDA applicant may attempt a Paragraph IV challenge against listed patents, pursue a Paragraph III certification for later entry, or file a section viii statement that omits a patented method of use. The resulting launch date will depend on the claims asserted and the litigation outcome.
Are there Paragraph IV challenges or generic litigation?
Publicly disclosed information through mid-2024 did not establish a major, market-defining US brigatinib generic litigation outcome comparable to the high-profile cases involving larger oncology products. The absence of a reported major judgment does not remove future risk. Generic applicants can file ANDAs before the composition patent expires, and litigation may begin after Takeda receives a Paragraph IV notice.
What generic launch scenarios exist?
| Scenario |
Likely timing logic |
Commercial effect |
| No successful Paragraph IV challenge |
After expiry of blocking patents |
Later generic entry with continued branded sales until expiry |
| Early settlement |
Date fixed by agreement |
Partial erosion before or after core patent expiry |
| Successful invalidity or non-infringement challenge |
Potentially before 2030 |
Rapid price and volume erosion |
| Section viii carve-out |
Generic launches without a patented indication |
Initial product availability may be limited by labeling |
| Multiple generic entrants |
After key patents expire |
Faster price erosion and lower brand retention |
The most important litigation risk is the core composition patent. Later formulation or method-of-use patents can delay some forms of competition, but they are generally more vulnerable to design-around strategies than a broad compound patent.
What formulation and method-of-use patents protect Alunbrig?
Alunbrig’s patent protection may extend beyond the molecule itself. Relevant categories include pharmaceutical compositions, tablet forms, dosing regimens and treatment methods for ALK-positive cancers.
Which brigatinib formulations are protected?
The marketed product is an oral tablet supplied in multiple strengths, including 30 mg, 90 mg and 180 mg tablets. The lead-in regimen uses 90 mg once daily for seven days, followed by 180 mg once daily. Formulation patents can claim a particular dosage form, excipient combination, crystalline form or manufacturing process.
Formulation protection is commercially useful when it prevents an ANDA applicant from copying the exact marketed presentation. It is less effective if a generic company can develop a bioequivalent tablet using a different composition.
Are method-of-use patents commercially important?
Method-of-use patents may cover treatment of ALK-positive metastatic NSCLC, use after crizotinib, first-line treatment or a specified dosing schedule. A generic applicant can sometimes omit a patented indication from its label through a section viii statement. That can narrow, but not necessarily eliminate, the practical risk of generic substitution.
Because brigatinib’s principal indications are closely connected to its approved use, method-of-use patents may have more commercial significance than they would for a product with many unrelated indications. Their enforceability still depends on claim scope and the prescribing behavior of physicians.
How strong is the brigatinib patent estate?
The estate has a potentially strong early layer if the core composition patent remains enforceable through about 2030. Later patents may extend nominal protection, but their practical value is lower if generic manufacturers can design around formulation or dosing claims.
Patent-strength assessment
| Factor |
Assessment |
| Core molecule patent |
Potentially strong if validity and infringement claims survive |
| Regulatory exclusivity |
Expired |
| Formulation protection |
Useful but more susceptible to design-around |
| Method-of-use protection |
Potentially meaningful; vulnerable to label carve-outs |
| Biosimilar protection |
Not applicable because brigatinib is a small molecule |
| Generic substitution risk |
Low before core patent challenge; high after effective patent expiry |
| Litigation leverage |
Dependent on Orange Book listings and claim breadth |
The overall estate is best characterized as moderately strong through the core patent term, with uncertain incremental value from secondary patents. The commercial durability of Alunbrig therefore depends more on first-line market share and clinical positioning than on late-cycle secondary patent protection alone.
What is the biosimilar risk for brigatinib?
Brigatinib does not face biosimilar competition. Biosimilars are regulated under the biologics pathway, while brigatinib is a chemically synthesized small molecule subject to the ANDA generic pathway.
The relevant risks are:
- ANDA filings.
- Paragraph IV patent challenges.
- Generic tablet substitution.
- Price discounting after patent expiry.
- Parallel erosion across US, European and Japanese markets.
This distinction matters for forecasting. Generic entry can occur more rapidly and produce steeper net-price erosion than biosimilar entry for many biologic products.
What licensing deals and ownership arrangements affect brigatinib?
Brigatinib originated with ARIAD Pharmaceuticals. Takeda acquired ARIAD in 2017 for approximately $5.2 billion, bringing brigatinib into Takeda’s oncology portfolio. The acquisition gave Takeda global control of the product and its associated intellectual property rather than relying on a conventional post-launch regional license (Takeda Pharmaceutical Company, 2017).
The transaction also placed Alunbrig within Takeda’s broader oncology strategy alongside products such as Iclusig. There is no major publicly disclosed external royalty structure that dominates the product’s economics in the way that some partnered medicines are affected by milestone payments or tiered royalties.
What litigation and settlement issues affect Alunbrig?
The main legal issues are likely to involve:
- Validity of the core compound patent.
- Infringement of formulation and dosage patents.
- Whether a generic label carve-out is adequate.
- The timing of any Paragraph IV notice.
- The terms of any confidential or publicly disclosed settlement.
A generic challenge could produce a 30-month stay if Takeda files an infringement action within the statutory period. A settlement could establish an authorized-generic date, a licensed generic launch date or other restrictions. No broadly reported US settlement has established an earlier brigatinib generic launch date through mid-2024.
What geographic markets drive brigatinib sales?
The United States is strategically important because it offers high oncology pricing and rapid uptake of first-line targeted therapies. Japan is also relevant to Takeda because of the company’s domestic commercial infrastructure. Europe and other international markets contribute through national reimbursement decisions and localized launch timing.
Geographic risk factors
| Region |
Main market factor |
Risk |
| United States |
High price, strong molecular testing, Orange Book litigation |
Largest patent and generic exposure |
| Japan |
Takeda commercial presence and reimbursement controls |
Lower pricing and formulary constraints |
| Europe |
Country-level health technology assessment |
Slower, uneven access |
| China and emerging markets |
Expanding diagnosis and targeted-treatment access |
Price controls and local competition |
Patent rights are territorial. US patent expiry does not automatically determine entry in Europe, Japan or other markets. Takeda’s revenue trajectory will therefore depend on different national patent terms, regulatory approvals and reimbursement calendars.
What manufacturing and intellectual-property barriers affect brigatinib?
Brigatinib is an oral small molecule, so manufacturing barriers are lower than for complex biologics. The principal barriers are:
- Reproducing the active pharmaceutical ingredient at commercial scale.
- Establishing bioequivalence for the tablet.
- Meeting impurity and stability specifications.
- Avoiding process and formulation patent claims.
- Securing regulatory approval for each strength.
- Demonstrating adequate supply reliability.
Manufacturing know-how may protect quality and yield, but it is unlikely to prevent a capable generic manufacturer from entering after key patents expire. Process patents can add friction but usually have less strategic value than a broad composition patent.
What generic entry risk exists for brigatinib?
The most plausible base case is continued branded sales through the primary patent term, followed by meaningful US generic risk around 2030 unless Takeda obtains enforceable later protection or reaches a settlement. A successful early Paragraph IV challenge would pull erosion forward.
Financial scenarios
| Scenario |
Revenue implication |
| Base case: no early challenge |
Growth or stability through the late 2020s, followed by sharp erosion after effective patent expiry |
| Competitive pressure without generic entry |
Slower growth as alectinib and lorlatinib limit share |
| Early generic launch |
Material US revenue decline before 2030 |
| Strong first-line retention |
Higher cumulative sales and greater exposure to later patent expiry |
| Late secondary-patent enforcement |
Possible limited delay, but not guaranteed full market protection |
After generic entry, branded oncology products commonly experience rapid volume migration and substantial net-price compression. The magnitude depends on the number of generic entrants, insurer substitution policies, specialty-pharmacy practices and whether Takeda launches or authorizes a generic alternative.
How does brigatinib compare with other Takeda assets?
Alunbrig is strategically useful but not a core revenue pillar. Takeda’s financial exposure is concentrated in larger products and therapeutic franchises. This limits group-level downside from brigatinib erosion but increases the importance of maintaining oncology growth and replacing products that approach loss of exclusivity.
Alunbrig also provides Takeda with a targeted-oncology platform and commercial access to ALK-positive specialists. Its value is higher than reported product sales alone because it supports portfolio breadth, physician relationships and oncology infrastructure. Those strategic benefits do not eliminate the product’s direct exposure to competitive displacement.
Key Takeaways
- Brigatinib is an established first-line and post-crizotinib therapy for ALK-positive metastatic NSCLC.
- The 2020 first-line FDA approval changed Alunbrig from a later-line product into a broader commercial asset.
- Takeda’s Alunbrig sales reached approximately ¥70 billion annually by FY2023, representing roughly 1% to 2% of Takeda’s consolidated revenue.
- Alectinib is the strongest commercial comparator, while lorlatinib creates additional pressure through CNS efficacy and durable disease-control data.
- FDA regulatory exclusivity expired in 2022; patent protection is more important for launch timing.
- U.S. Patent No. 8,426,586 is associated with protection extending to approximately 2030 before applicable adjustments.
- Later formulation, dosage and method-of-use patents may extend nominal protection into the mid-2030s but are more vulnerable to design-around and label-carve-out strategies.
- Brigatinib faces generic, not biosimilar, risk.
- No broadly reported US Paragraph IV settlement had established an earlier generic launch date through mid-2024.
- The central investment variable is first-line market share retention through the late 2020s, followed by the timing and scope of generic erosion.
FAQs About Brigatinib Market and Patent Risk
What is the brand name for brigatinib?
Brigatinib is marketed under the brand name Alunbrig by Takeda Pharmaceutical.
Is brigatinib still used after crizotinib?
Yes. The FDA-approved label includes treatment of metastatic ALK-positive NSCLC after progression on crizotinib, as well as first-line treatment.
Does brigatinib have orphan-drug exclusivity?
Brigatinib’s commercial protection is principally based on patents and standard FDA regulatory exclusivity rather than a publicly central seven-year orphan-drug exclusivity period.
Which drug is the biggest competitor to brigatinib?
Alectinib, marketed as Alecensa by Roche, is generally the most direct first-line commercial competitor. Lorlatinib, marketed as Lorbrena by Pfizer, is another major competitive threat.
Can a generic manufacturer copy Alunbrig’s seven-day lead-in regimen?
A generic manufacturer may seek approval for the relevant dosing regimen, but the ability to copy the exact regimen depends on applicable patent claims, Orange Book listings, labeling strategy and litigation outcomes.
References
Camidge, D. R., Kim, H. R., Ahn, M. J., Yang, J. C. H., Han, J. Y., Lee, D. H., Hochmair, M. J., Li, J. Y., Chang, G. C., Lee, K. H., Gridelli, C., Delmonte, A., Garcia Campelo, M. R., Felip, E., Kim, D. W., Lin, C. C., Schuler, M. K., Gonzalez, F. J., Min, Y. J., ... Ou, S. H. I. (2018). Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. New England Journal of Medicine, 379(21), 2027-2039. https://doi.org/10.1056/NEJMoa1810171
U.S. Food and Drug Administration. (2017). FDA approves brigatinib for metastatic ALK-positive non-small cell lung cancer. https://www.fda.gov
U.S. Food and Drug Administration. (2020). FDA approves brigatinib for first-line treatment of ALK-positive metastatic non-small cell lung cancer. https://www.fda.gov
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
Takeda Pharmaceutical Company Limited. (2017). Takeda to acquire ARIAD Pharmaceuticals, Inc. https://www.takeda.com
Takeda Pharmaceutical Company Limited. (2024). Annual report and integrated report 2024. https://www.takeda.com/investors/financial-results/annual-reports/
